Stabilux Biosciences

StabiLux Biosciences is an early-stage biotech firm pioneering a nanoparticle-based dye platform to dramatically improve biomarker detection sensitivity. Founded in 2020, the company leverages proprietary boron nitride nanoparticles to create 'StabiLux Bright Technology,' which can be conjugated with existing dyes and biomolecules like antibodies and RNA. This platform targets critical unmet needs in early cancer detection, immunology research, and therapeutic development by enabling researchers to 'detect the undetectable.' The company appears to be in a pre-revenue, platform-validation stage, building on over a decade of academic research from Michigan Technological University.

High-brightness fluorescent dye platform based on optically transparent, electrically non-conductive boron nitride nanoparticles. The platform conjugates dyes and biomolecules (antibodies, RNA, proteins) to the nanoparticles for amplified signal in detection applications.

StabiLux competes in the large and established market for fluorescent dyes and probes dominated by companies like Thermo Fisher, Abcam, and PerkinElmer. It also competes with other emerging companies developing nanoparticle-based or signal-amplification detection technologies. Its differentiation hinges on the unique material properties of boron nitride.